45
BIBLIOGRAFIA
1. Hunter T. Signaling-2000 and beyond. Cell 2000;100:113-27.
2. Pawson T, Nash P. Protein-protein interactions define specificity in signal transduction.
Genes Dev 2000;14:1027-47.
3. Furnari, F. B., Lin, H., Huuang, H.-J. S. & Cavenee, W.K. (1997) Proc. Natl. Acad. Sci.
USA 94, 12479-12484.
4. Cheney, I.W., Johnson, D. E., Vaillancoort, M.-T., Avanzini, J., Morimoto, A., Demers, G.
W., Wills, K. N., Shabram, P. W., Bolen, J. B., Tavtigian, S. V. & Bookstein, R. (1998) Cancer Res 58, 2331-2334.
5. Cantley and Neel. New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. Proc. Natl. Acad. Sci. Usa 96 (1999).
6. Klippel, A., Kavanaugh, W. M., Pot, D. & Williams, L. T. (1997) Mol. Cell. Biol. 17, 338- 344.
7. Alessi, D. R., Desk, M., Casamayor, A., Caudwell, F. B., Morrice, N., Norman, D. G., Gaffney, P. & Reese, C. B. (1997) Curr. Biol. 7, 776-789.
8. Hunter T. Signaling-2000 and beyond. Cell 2000;100:113-127.
9. Lynch DK, Ellis CA, Edwards PA, Hiles ID. Integrin-linked kinase regulates phosphorilation of serin 473 of protein kinase B by an indirect mechanism. Oncogene 1999;
18: 8024-8032.
10. Persad S, Attwell S, Gray V, et al. Regulation of protein kinase B/Akt-serine 473 phosphorilation by integrin-linked kinase: Critical roles for kinase activity and amino acids arginine 211 and serine 343. J Biol Chem 2001; 276:27462-27469.
11. Delcommenne M, Tan C, Gray V, et al. Phosphoinositide-3-OH kinase-dependent regulation of glycogen synthase kinase 3 and protein kinase B/AKT by the integrin-linked kinase. Proc Natl Acad Sci USA 1998: 11211-11216.
12. Meier R, Hemmings BA. Regulation of protein kinase B. J Recept Signal Transduct Res 1999;19:121-8.
13. Datta, S. R., Dudek, H., Tao, X., Masters, S., Fu, H., Gotoh, Y. & Greenberg, M. E. (1997) Cell 91, 231-241.
14. Diehl JA, Cheng M, Roussel MF, Sherr CJ. Glycogen synthase kinase-3beta regulates cyclin D1 proteolysis and subcellular localization. Genes Dev 1998;12:3499-511.
15. Myers, M. P., Puss, I. H., Vander Kaay, J., Stolarow, J. P., Hemmings, B. A., Wigler, M. H., Downes, C. P. & Tonks, N. K. (1998) Proc. Natl. Acad. Sci. USA 95, 13513-13518.
16. Wu, X., Senechal, K., Neshat, M. S., Whang, Y. E. & Sawyers, C. L. (1998) Proc. Natl.
Acad. Sci. USA 95, 15587-15591.
17. Stambolic, V., Suzuki, A., de la Pompa, J. L., Brothers, G. M., Mirtsos, C., Sasaki, T., Ruland, J., Penninger, J. M., Siderovski, D. P. & Mak, T. W. (1998) Cell 95, 29-39.
18. Suzuki, A., de la Pompa, J. L., Stambolic, V., Elia, A. J., Sasaki, T., del Barco, Barrantes, l., Ho, A., Wakeham, A., Itie, A., Khoo, W., et al. (1998) Curr. Biol. 8, 1169-1178.
19. Wymann MP, Bulgarelli-Leva G, Zvelebil MJ, Pirola L, Vanhaeesebroeck B, Waterfield MD et al. (1996). Wortmannin inactivates phosphoinositide 3-kinase by covalent modification of Lys-802, a residue involved in the phosphate transfer reaction. Mol Cell Biol 16:1722-1733.
20. Hu L, Hofmann J, Lu Y, Mills GB, Jaffe RB. Inhibition of phosphatidylinositol 3'-kinase increases efficacy of paclitaxel in vitro and in vivo ovarian cancer models. Cancer Res 2002;62:1087-92.
46
21. Ng SSW, Tsao MS, Chow S, Hedley DW. Inibition of phosphatidylinositide 3'-kinase enhances gemcitabine-induced apoptosis in human pancreatic cancer cells. Cancer Res 2000:5451-5.
22. Rosenzweig KE, Youmell MB, Palayoor ST, Price BD, Radiosensitization of human tumor cells by the phosphatidylinositol-3-kinase inhibitors wortmannin and LY294002 correlates with inhibition of DNA-dependent protein kinase and prolonged G2-M delay. Clin Cancer Res 1997;3:1149-56.
23. Sarkaria JN, Tibbetts RS, Busby EC, et al. Inhibition of phosphoinositide 3-kinase related kinases by the radiosensitizing agent wortmannin. Cancer Res 1998;58:4375-82.
24. Kim SH, Um JH, Dong-Won B, et al. Potentiation of chemosensitivity in multidrug-resistant human leukaemia CEM cells by inhibition of DNA-dependent protein kinase using wortmannin. Leuk Res 2000;24:917-25.
25. Wang Q, Li N, Wang X, Kim MM, Evers BM. Augmentation of sodium butyrate-induced apoptosis by phosphatidylinositol 3'-kinase inhibition in the KM20 human colon cancer cell line. Clin Cancer Res 2002;8:1940-7.
26. Brognard J, Clark AS, Ni Y, Dennis PA. Akt/protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation. Cancer Res 2001;61:3986-97.
27. Clark AS, West K, Streicher S, Dennis PA. Constitutive and inducible Akt activity promotes resistance to chemotherapy, trastuzumab, or tamoxifen in brast cancer cells. Mol Cancer Ther 2002;1:707-17.
28. Staal SP.Molecular cloning of the akt oncogene and its human homologues AKT1 and AKT2:amplification of AKT1 in a primary human gastric adenocarcinoma. Proc Natl Acad Sci USA 1987;84:5034-7.
29. Murthy SS, Tosolini A, Taguchi T, Testa JR. Mapping of AKT3, encoding a member of the Akt/protein kinase B family, to human and rodent chromosomes by fluorescence in situ hybridization. Cytogenet Cell Genet 2000;88:38-40.
30. Thomas, C.; Deak, M.; Alessi, D.R.; Alten, D.M.; High resolution structure of the PH domain of PKB/Akt boun to phosphetidylinositol (3,4,5)-triphosphate. Curr.Biol. 2002, 12, 1256-1262.
31. Davies, Verdonk, Graham. Saalau-Bethell, Hamlett, McHardy Collins, Garret, Workman, Woodhead, Jhoti, Barford; a structural comparison of inhibitor binding to PKB, PKA and PKA-PKB chimera. J. Mol. Biol. (2007) 367, 882-894.
32. Alessi DR, James SR, Downes CP, Holmes AB, Gaffney PRJ, Reese CB et al. (1997).
Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase B. Curr Biol 7:261-269.
33. Stephens L, Anderson K, Stokoe D, Erdjument-Bromage H, Painter GF, Holmes AB et al.(1998). Protein kinase B kinases that mediate phoshatidylinositol 3,4,5-trisphosphate- dependent activation of protein kinase B. Science 279:710-714.
34. C Garcia-Echeverria and WR Sellers; Drug discovery approaches targeting the PI3K/Akt pathway in cancer. Oncogene (2008) 27, 5511-5526.
35. Peifer, Alessi; Small-Molecule Inhibitors of PDK1. ChemMedChem 2008, 3, 1810-1838.
36. Altomare Deborah et al. Akt and Mtor phosphorylation is frequently detected in ovarian cancer and can be targeted to distrupt ovarian tumor cell growth. Oncogene 2004, 23, 5853 37. Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, Staroslawska E, Sosman
J, McDermott D, Bodrogi I et al.: Temsirolimus, Interferon alfa, or both for advanced renal- cell carcinoma. N Engl J Med 2007, 356: 2271-2281.
38. Holland EC. Glioblastoma multiforme: the terminator. Proc Natl Acad Sci USA 2000; 97:
6242-4.
47
39. Mather EA, Furnari FB, Bachoo RM, et al. Malignant glioma: genetics and biology of a grave matter. Genes Dev 2001; 15: 1311-33.
40. Wechsler-Reya R, Scott MP. The developmental biology of brain tumors. Annu Rev Neurosci 2001; 24: 385-428.
41. Haas-Kogan D, Shalev N, Wong M, Mills G, Yount G, Stokoe D. Protein kinase B (PKB/Akt) activity is elevated in glioblastoma cells dueto mutation of the tumor suppressor PTEN/MMAC. Curr Biol 1998; 8: 1195-8.
42. Rajasekhar VK, Viale A, Socci ND, Wiedmann M, Hu X, Holland EC. Oncogenic Ras and Akt signalling contribute to glioblastoma formation by differential recruitment of existing mRNAs to polysomes. Mol Cell 2003; 12:889-901.
43. Hildebrandt et al. J Clin Oncol 2009; 27: 857-71.
44. Che net al. Mol Cancer Ther 2008; 7 (4): 841-50 2008.
